TAAS Stock – ImmunityBio : Immunotherapy vaccine shows promise in prostate cancer patients
The company’s hAd5 is designed to deliver tumour-associated antigens (TAAs) and neoepitopes (expressed only by cancer cells) and induce T-cell and antibody responses that may result in T-cell memory.
The study (NCT03481816) enrolled 18 patients with mCRPC who had advanced, incurable disease. They were given concurrently three hAd5 vaccines targeting prostate-specific antigen (PSA), brachyury and MUC-1 at a dose of 5×1011 viral particles (VPs) each, subcutaneously every three weeks for a maximum of three doses (dose de-escalation cohort), followed by a booster vaccine every eight weeks for a year (dose-expansion cohort only).
According to investigators, one patient achieved a partial response and five had confirmed stable disease (SD) for over six months, with confirmed PSA decline. Additionally, the median progression-free survival was 22 weeks, median overall survival (OS) was not reached and the 12-month OS probability for all patients was 83.3 percent.
Furthermore, all 17 patients included in the analysis mounted T-cell responses to at least one tumour-associated antigen and 94 percent (16 of 17) developed T-cell responses to more than one antigen encoded by the vaccine.
“The finding of T-cell-mediated immunity induced in 100 percent of 17 prostate cancer patients whose white blood cells were evaluated in the study validates the ability of our hAd5 vaccine platform to generate a potent response to antigens delivered,” stated Dr
The post Immunotherapy vaccine shows promise in prostate cancer patients appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2021. All Rights Reserved., source